Small stocks vaulted higher than the broader market on Wednesday, largely on positive earnings from names such as TTM Technologies ( TTMI).

The Santa Ana, Calif., maker of printed circuit boards soared more than 29% to $11.85 after reporting that first-quarter profits totaled $8.5 million, or 20 cents a share -- 15 cents higher per share than Wall Street's consensus, according to Thomson Financial.

Joining TTM in the green zone were fellow tech stocks Voxware ( VOXW), a business-software firm, and Mountain View, Calif., semiconductor company Cavium Networks ( CAVM).

New Jersey-based Voxware tripled its value to $6.83 after saying it swung to a first-quarter profit of $685,000, or a dime a share, from a 34-cent per-share loss last year. Sales nearly doubled to $3.6 million. Cavium, meanwhile, vaulted 24.2% to $16.76 following its initial public offering of 6.75 million shares, plus an underwriter's option for about another million in order to cover any overallotments.

Buffalo Wild Wings ( BWLD), a Minneapolis-based restaurant chain, likewise handily beat Wall Street expectations with mounting first-quarter profits of $5.5 million, or 63 cents a share. Its stock jumped 14.4% to $74.19. LoJack ( LOJN), a Westwood, Mass., maker of security equipment, more than doubled its profits year over year to 32 cents a share -- a dime over estimates. Shares shot up $2.21, or 12.2%, to $20.31.

Florida-based Nabi Biopharmaceuticals ( NABI) was also rising after a phase IIb trial of NicVax -- its proposed treatment for nicotine addiction -- achieved its primary endpoint. Shares surged 12.7% to $5.79. Elsewhere in the health sector, California's Pain Therapeutics ( PTIE) gained 13.1% to $8.65 after it posted a 28-cent per-share profit in the first quarter, which powered past analysts' downside expectations.

Among small-cap health laggards, however, was CollaGenex Pharmaceuticals ( CGPI), which said a patient in midphase testing for its proposed acne treatment, incyclinide, sustained "apparent significant photo-toxicity" -- a severe reaction to sunlight and "a known side effect of tetracyclines," of which incyclinide is a modified form. The Newton, Pa., drugmaker is investigating the incident and, in the interim, has halted further enrollment in the study. Shares were losing more than 18% at $11.45.

Meanwhile, Canada's Neurochem ( NRMX) slid 16% to $9.74 on word it privately sold $80 million in convertible bonds, and fellow drugmaker Santarus ( SNTS), of San Diego, was off 12.3% at $6.95 after losing 3 cents more per share in the first quarter than Wall Street had predicted.

Returning to the tech sector, real-estate Web site Move ( MOVE) broke even in the first quarter, missing analysts' projections by 2 cents despite gaining 2 cents on last year. The California-based company recently plunged 10% to $4.23. And Florida-based Forward ( FORD), which makes accessories for handheld electronics, swung to a small loss from penny-a-share profits a year ago. Shares sank 15% at $3.40.

The Russell 2000 Index lately jumped 12.09 points, or 1.5%, to 828.34. The S&P Small-Cap 600 Index gained 6.79, or 1.6%, at 429.57.

If you liked this article you might like

Lackluster Finish for U.S. Stocks

Lackluster Finish for U.S. Stocks

Stocks Continue to Waver at the Flat Line

Stocks Continue to Waver at the Flat Line

Oil Slides as Stocks Post a Mixed Showing

Oil Slides as Stocks Post a Mixed Showing

Stocks Flutter Near the Flat Line

Stocks Flutter Near the Flat Line

Wall Street Falls Amid Inflation Talk

Wall Street Falls Amid Inflation Talk